In patients with primary estrogen receptor α-positive (ERα+) breast cancer (BC), ZBTB20 has been identified as a significantly downregulated gene in biopsies upon treatment of aromatase inhibitors [109], whereas in ERα+ BC cell lines, ZBTB20 is upregulated after treatment of anacardic acid, emphasizing that the roles of ZBTB20 could be treatment- and context-specific in BC [110]. Here, ZBTB20 is linked to breast carcinoma.